GSK Jan 2025 25.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:34AM EDT. Market open.
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 988 |
ZacksGSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CityAMUS regulator accepts GSK’s application to expand treatment of cancer drug
The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.
Fool.co.ukIs this FTSE growth superstar set to soar even higher on new drug results?
New drugs should significantly boost this FTSE stock’s earnings in my view. But even without them it looked very undervalued to me. The post Is this FTSE growth superstar set to soar even higher on new drug results? appeared first on The Motley Fool UK.
© 2024 Yahoo. All rights reserved.